Public disclosures

GNVR insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
Kalkofen Donald A.

Chief Financial Officer · Genvor Inc

GNVR

Genvor Inc

Equity grant or award
Filing details

SEC transaction code A

Nonqualified Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 575000 · The exercise price equals the fair market value of a share of common stock on the date of grant, determined under the Issuer's 2026 Omnibus Equity Incentive Plan as the average of the closing bid and asked prices on the OTCQB market for the last preceding date on which there was a sale, which was November 18, 2026. · Share amounts are stated before any reverse stock split. The number of shares subject to the option and the exercise price are subject to proportionate adjustment under the Plan for any reverse stock split or other change in capitalization. · The option was granted under the Issuer's 2026 Omnibus Equity Incentive Plan pursuant to the Reporting Person's Amended and Restated Acting Chief Financial Officer Services Agreement dated May 21, 2026. As to 425,000 shares, the option vests in twelve equal monthly installments on each monthly anniversary of May 18, 2026, with installments whose vesting dates preceded the grant date vested on the grant date; as to 150,000 shares, the option vests in full upon an Uplisting Event as defined in that agreement. The option may not be exercised until a registration statement on Form S-8 covering the underlying shares has become effective. The grant was approved by the Issuer's Board of Directors and is exempt under Rule 16b-3(d).

2026-11-192026-11-20

575,000 shares/units

SEC 4Follow
Yates Clayton Clopton

Director · 10% owner · Genvor Inc

GNVR

Genvor Inc

Equity grant or award
Filing details

SEC transaction code A

Common Stock · Indirect ownership · ACT Holdings, LLC · Reported balance after transaction: 600000 · Shares issued upon Dr. Yates' conversion of $100,000 in outstanding payables owed by the Company to Dr. Yates, pursuant to his scientific advisor agreement with the Company and the Company's restructured compensation package previously approved by the Company, which permits Dr. Yates to convert amounts due to him into Company common stock. · Dr. Yates has voting and dispositive power with respect to shares held in the name of ACT Holdings, LLC, and is therefore deemed to be beneficial owner of shares held in its name.

2026-04-152026-11-03

200,000 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement